Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Asset Writedowns and Impairment (2020 - 2025)

Biofrontera has reported Asset Writedowns and Impairment over the past 6 years, most recently at -$25000.0 for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at -$25000.0 for Q4 2025, down 149.02% from a year ago — trailing twelve months through Dec 2025 was -$69000.0 (down 142.59% YoY), and the annual figure for FY2025 was -$69000.0, down 142.59%.
  • Asset Writedowns and Impairment for Q4 2025 was -$25000.0 at Biofrontera, down from $13000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for BFRIW hit a ceiling of $94000.0 in Q3 2023 and a floor of -$46000.0 in Q1 2025.
  • Median Asset Writedowns and Impairment over the past 5 years was $12000.0 (2024), compared with a mean of $17700.0.
  • Peak annual rise in Asset Writedowns and Impairment hit 4650.0% in 2022, while the deepest fall reached 833.33% in 2022.
  • Biofrontera's Asset Writedowns and Impairment stood at -$3000.0 in 2021, then crashed by 66.67% to -$5000.0 in 2022, then crashed by 620.0% to -$36000.0 in 2023, then surged by 241.67% to $51000.0 in 2024, then plummeted by 149.02% to -$25000.0 in 2025.
  • The last three reported values for Asset Writedowns and Impairment were -$25000.0 (Q4 2025), $13000.0 (Q3 2025), and -$11000.0 (Q2 2025) per Business Quant data.